{"entity":{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","aka":[],"tldr":"BigHat uses machine learning and a fast automated lab to design antibodies. Its first cancer drug, an antibody carrying a chemotherapy payload to stomach and bowel tumours, entered human trials in 2026.","summary":"BigHat Biosciences, based in San Mateo, California, is an AI-native antibody company. Its Milliner platform pairs a synthetic biology wet lab that can synthesise, purify and characterise hundreds of antibodies a week with machine learning that proposes the next designs. Lead programme BHB810 is a CDH17-directed VHH-Fc antibody-drug conjugate with a compact antibody format and a stable payload; across about 30 patient- and cell-derived tumour models it produced complete or near-complete tumour clearance, and the first patient was dosed in a phase 1 dose-escalation trial in gastric, gastro-oesophageal junction and other advanced gastrointestinal tumours on 1 September 2026. BigHat has completed collaborations with Merck and Johnson and Johnson and partners with Eli Lilly through Lilly TuneLab. The company describes itself as a Series B company that has raised more than USD 100 million; round details were not on fetched pages.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bighatbio.com"},{"label":"First patient dosed with BHB810 (September 2026)","url":"https://bighatbio.com/news/bighat-biosciences-announces-first-patient-dosed-in-phase-1-trial-evaluating-bhb810"},{"label":"News","url":"https://bighatbio.com/news"}],"tags":[],"related":[],"cancers":["gastric","esophageal","colorectal"],"sections":["adcs","ai-computation","drug-discovery"],"technologies":["adc","monoclonal-antibody","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07529808"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Colorectal included because the trial covers advanced gastrointestinal tumours broadly; specific enrolment beyond gastric and GEJ not confirmed. Founding year and round amounts not sourced."],"hq":"San Mateo, CA","country":"US","companyType":"biotech","website":"https://www.bighatbio.com","stage":"startup","investors":[],"funding":[]},"route":"/companies/bighat-biosciences/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"trial":[{"id":"nct07529808","kind":"trial","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","route":"/trials/nct07529808/"}]}}